Table 1 Baseline characteristics of patients with bronchiectasis and airflow obstruction treated with inhaled combination therapies
|  | ICS/LABA/LAMA (n = 58) | ICS/LABA (n = 52) | LABA/LAMA (n = 69) | P-value |
|---|---|---|---|---|
Age, mean (SD) | 61.05 (10.35) | 62.60 (12.19) | 63.81 (11.34) | 0.392 |
Female, n (%) | 7 (12.1) | 20 (38.5) | 15 (21.7) | 0.004 |
BMI, mean (SD) | 20.44 (4.06) | 22.86 (4.42) | 21.86 (3.66) | 0.011 |
Smoking history | Â | Â | Â | Â |
Never smoker, n (%) | 10 (17.2) | 20 (38.5) | 25 (36.2) | 0.025 |
Ex-smoker, n (%) | 25 (43.1) | 18 (34.6) | 29 (42.0) | 0.615 |
Current smoker, n (%) | 23 (39.7) | 14 (26.9) | 15 (21.7) | 0.079 |
Pack years, median (IQR) | 30 (22–38) | 15 (9–21) | 20 (14–26) | 0.002 |
Disease severity | Â | Â | Â | Â |
mMRC score, mean (SD) | 2.09 (0.82) | 1.63 (0.66) | 1.75 (0.81) | 0.007 |
BSI score, mean (SD) | 7.91 (3.75) | 5.29 (2.80) | 6.06 (3.25) | < 0.001 |
FACED score, mean (SD) | 2.66 (1.66) | 1.63 (1.69) | 2.29 (1.48) | 0.004 |
Previous moderate or severe exacerbation history, n (%) | 24 (43.6) | 14 (29.2) | 14 (20.3) | 0.019 |
Bacterial colonizer, n (%) | 21 (36.2) | 14 (26.9) | 21 (30.4) | 0.566 |
Pseudomonas colonizer, n (%) | 7 (12.1) | 2 (3.8) | 6 (9.2) | 0.298 |
Comorbidity | Â | Â | Â | Â |
Hypertension, n (%) | 24 (41.4) | 24 (46.2) | 33 (47.8) | 0.759 |
Diabetes mellitus, n (%) | 11 (19.0) | 17 (32.7) | 20 (29.0) | 0.234 |
Chronic kidney disease, n (%) | 6 (10.3) | 3 (5.8) | 6 (8.7) | 0.683 |
Chronic liver disease, n (%) | 6 (10.3) | 7 (13.5) | 10 (14.5) | 0.775 |
Cerebrovascular disease, n (%) | 6 (10.3) | 6 (11.5) | 7 (10.1) | 0.967 |
Cardiovascular disease, n (%) | 9 (15.5) | 13 (25.0) | 14 (20.3) | 0.464 |
Lung cancer, n (%) | 7 (12.1) | 4 (7.7) | 15 (21.7) | 0.077 |
Malignancy other than lung cancer, n (%) | 10 (17.2) | 12 (23.1) | 9 (13.0) | 0.353 |
Duration of inhaled combination therapy, month, mean (SD) | 62.81 (39.15) | 55.96 (44.83) | 33.34 (17.63) | < 0.001 |